Jounce Therapeutics (NASDAQ:JNCE – Get Rating) and Kymera Therapeutics (NASDAQ:KYMR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations. Institutional & Insider Ownership 80.7% of Jounce Therapeutics shares […]
StockNews.com initiated coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report sent to investors on Thursday. The firm issued a hold rating on the stock. Several other analysts have also commented on the stock. Piper Sandler lowered shares of Jounce Therapeutics from an overweight rating to a neutral rating in […]
Investment analysts at StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James cut shares of Jounce Therapeutics from an “outperform” rating to a “market […]
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the stock. A number of other analysts have also issued reports on JNCE. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in […]